← All trials
NCT03996772
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 3, 2019
- Primary completion
- Jul 31, 2022
- Completion date
- Jul 31, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 654
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Imperial College LondonLead sponsor
- University of CambridgeCollaborator
- Universidad Autonoma de BarcelonaCollaborator
- University of LondonCollaborator
- Medical University of GrazCollaborator
- Julius-Maximilians UniversityCollaborator
- University of PerugiaCollaborator
- University of HullCollaborator
- University of LiverpoolCollaborator
- University of BirminghamCollaborator
- Aalborg UniversityCollaborator
- University Hospital Plymouth NHS TrustCollaborator
- West Hertfordshire Hospitals NHS TrustCollaborator
- University of HeidelbergCollaborator
- Imperial College LondonOverall official - principal investigator
- East Kent Hospitals University NHS Foundation TrustCollaborator
- University of BordeauxCollaborator
- Taunton and Somerset NHS Foundation TrustCollaborator
- STROKE ALLIANCE FOR EUROPECollaborator
- Northumbria Healthcare NHS Foundation TrustCollaborator
- Mid Yorkshire Hospitals NHS TrustCollaborator
- Basildon and Thurrock University Hospitals NHS Foundation TrustCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.